Alpine Immune Sciences, Inc. (ALPN) earnings
Quarterly and annual ALPN reports and results, each read against the price at its own news timestamp. Back to the ALPN overview →
6 measured ALPN earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Alpine Immune Sciences Reports First Quarter 2024 Financial Results | Press release | -0.01% | +0.00% | |
| Form 10-Q ALPINE IMMUNE SCIENCES, For: Mar 31 | SEC filing · Form 10-Q | -0.01% | +0.00% | |
| Form 10-K/A ALPINE IMMUNE SCIENCES, For: Dec 31 | SEC filing · Form 10-K | -0.01% | -0.06% | |
| Form 10-K ALPINE IMMUNE SCIENCES, For: Dec 31 | SEC filing · Form 10-K | +2.31% | -0.15% | |
| Alpine Immune Sciences Reports Third Quarter 2023 Financial Results | Press release | +3.22% | -0.94% | |
| Form 10-Q ALPINE IMMUNE SCIENCES, For: Sep 30 | SEC filing · Form 10-Q | +3.22% | -0.94% |
Keep exploring
More ALPN: analyst actions → · SEC filings → · ALPN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 173 | 0.00% | 49% |
| Aytu BioPharma, Inc. (AYTU) | 172 | -0.14% | 40% |
| NuCana plc - American Depositary Shares (NCNA) | 171 | -1.28% | 40% |
| UCB SA NPV (UCBJF) | 171 | 0.00% | 3% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.